Every compound and cycling protocol referenced on this page is discussed strictly for in vitro research and laboratory use. None are described for human consumption, therapeutic use, or veterinary application. Cycling information is presented as pharmacological reference, not as dosing guidance for humans or animals.
Why Peptides Are Cycled at All
Peptide cycling — running a peptide for a defined period, stopping for another defined period, then resuming — is one of the most-repeated pieces of advice in the peptide space, and one of the least-explained. The rule "cycle 8 weeks on, 4 weeks off" gets applied uniformly to peptides that need it, peptides that don't, and peptides for which the concept doesn't cleanly apply at all.
The real reason cycling exists is pharmacological, not conventional. Certain receptors — the ones peptides act on — reduce their responsiveness when they are continuously stimulated. Cycling exists to work around this. When the mechanism does not apply, cycling doesn't accomplish anything.
This page is organized around that framing: understand the mechanism, and the cycling protocol for any given peptide becomes readable rather than arbitrary.
The Mechanism: Receptor Desensitization
When a peptide binds a receptor and activates it, that is a signal. Cells are designed to notice signals — which means, by design, they are also good at tuning them out. A signal that stays on indefinitely stops being informative, and the cell reduces its response.
Three distinct mechanisms drive this, on different timescales:
1. Acute desensitization (minutes to hours)
The fastest mechanism. Immediately after a G protein-coupled receptor is activated, intracellular kinases (particularly GRKs — G protein-coupled receptor kinases) modify the receptor to make it temporarily unresponsive. It is still on the cell surface but no longer signaling. Removing the peptide allows the modification to reverse within minutes to hours. This is why pulsatile dosing — several administrations spaced through the day — often outperforms a single sustained infusion.
2. Internalization (hours to days)
Continued activation triggers the cell to physically pull the receptor off its surface and bring it inside. The receptor is not destroyed — it is sequestered. Without surface receptors, the signal cannot land. Internalization reverses on a slower timescale than acute desensitization, as the receptor is either recycled back to the surface or degraded.
3. Downregulation (days to weeks)
Under sustained continuous stimulation, cells reduce their synthesis of the receptor. The total pool of receptors — surface plus internal — shrinks. Reversing downregulation requires the cell to ramp receptor production back up, which is why the "off" portion of a cycle is measured in weeks rather than hours.
Pulsatility & the Natural Rhythm Argument
Endogenous hormones are not released continuously. Growth hormone is released in pulses — several bursts through a 24-hour cycle, with the largest during deep sleep. Cortisol follows a strong diurnal rhythm. GnRH is released in discrete pulses that the pituitary translates into LH and FSH. This pulsatility is not incidental — it is the way the system works, and it is designed specifically to prevent the desensitization described above.
Continuous stimulation flattens the rhythm. A GnRH agonist administered continuously actually shuts down LH and FSH release rather than stimulating it — a well-established pharmacological principle used medically for exactly this reason. Continuous stimulation of the ghrelin receptor blunts endogenous ghrelin pulsatility. The pattern of the signal matters, not just its presence.
This is why peptide protocols for GH-releasing peptides typically involve multiple daily doses rather than one long-acting depot. Ipamorelin at 100 mcg three times per day preserves receptor sensitivity better than 300 mcg once per day, even though the total dose is identical. The peptide's short half-life is not a limitation — it is a feature that supports the natural rhythm.
Cycling by Peptide Class
The class-level summary — organized by the mechanism that determines whether cycling is required.
| Class | Represented Peptides | Cycling Necessity | Reason |
|---|---|---|---|
| GHRH analogs | Sermorelin, CJC-1295, Tesamorelin | Recommended | Pituitary somatotroph responsiveness benefits from off periods |
| Ghrelin receptor agonists | Ipamorelin, GHRP-2/6, MK-677 | Recommended | Ghrelin receptor is known to desensitize under sustained stimulation |
| Melanocortin agonists | PT-141, Melanotan II | Event-based use typical | Melanocortin receptors tolerate infrequent doses well; continuous use uncommon |
| Healing peptides | BPC-157, TB-500, GHK-Cu | Window-based, not cycled | Mechanism does not appear to drive desensitization; used through a tissue-repair window |
| GLP-1 receptor agonists | Semaglutide, Tirzepatide, Retatrutide | Continuous use typical | Receptor system tolerates sustained agonism; long half-lives enable weekly dosing |
| Nootropic peptides | Semax, Selank | Course-based or continuous | Different mechanisms; conventions vary and are less firmly established |
| Mitochondrial peptides | MOTS-c, SS-31, Humanin | Not clearly established | Non-receptor mechanism; conventional cycling logic does not directly apply |
| Reproductive axis peptides | Gonadorelin, Kisspeptin-10 | Pulsatile dosing critical | Continuous agonism shuts down the axis rather than stimulating it |
| Growth factors | IGF-1 LR3, IGF-1 DES, MGF | Cycled in research contexts | Sustained IGF-1R activation raises separate concerns beyond desensitization |
"Recommended" reflects prevailing convention in published protocols, not universal rule. "Not clearly established" reflects the honest state of the literature for that class — cycling patterns exist by extrapolation rather than by mechanism-based study.
GH Secretagogues — Requires Cycling
The class where the pharmacological argument for cycling is strongest. Both major GH-releasing pathways — GHRH analogs and ghrelin receptor agonists — target receptors that are known to desensitize under sustained agonism, on top of a system that normally functions through pulsatile release.
Why this class specifically
The GH axis is under tight physiological regulation. Somatotrophs in the pituitary release GH in discrete bursts, with the timing and amplitude controlled by the interplay between GHRH (stimulatory), somatostatin (inhibitory), and ghrelin (stimulatory). Continuous stimulation of the receptors involved in this axis disrupts the normal rhythm on multiple timescales at once:
- Acute desensitization of the GHRH receptor within hours of continuous agonism
- Ghrelin receptor internalization under sustained GHS-R activation
- Downregulation of both receptors over weeks of continuous use
- Loss of endogenous pulsatile release patterns
The conventional pattern — 8 to 12 weeks on, followed by 4 weeks off — is not a magic number; it is a practical compromise that reflects roughly how long the axis can tolerate continuous stimulation before responsiveness drops meaningfully, and how long a break the axis needs to substantially recover.
Two representative cycling patterns for GH-releasing peptide research protocols. On periods vary by protocol; off periods trend toward ~4 weeks. The pattern, not the exact week count, is the pharmacological point.
Within-cycle: the pulsatility question
Even within an "on" cycle, dosing pattern matters. GH-releasing peptides with short half-lives (Ipamorelin ~2 hours, Sermorelin ~10–20 min, CJC-1295 no DAC ~30 min) are typically dosed multiple times per day to mimic pulsatile release rather than saturating the receptors continuously. See the Half-Life Reference for how half-life determines dosing rhythm.
CJC-1295 with DAC (half-life ~6–8 days) is a specific exception — it produces sustained rather than pulsatile stimulation, which is part of why its use is more debated within this class.
Melanocortin Agonists — Event-Based Use
Melanocortin agonists are typically used episodically rather than continuously, which means the cycling question rarely arises in the same form as with GH secretagogues.
PT-141 (Bremelanotide) is characteristically used event-based in research protocols — an administration when the studied response is intended, rather than a daily maintenance schedule. This natural intermittent use avoids the desensitization question that makes cycling relevant elsewhere.
Melanotan II protocols in research contexts tend toward short courses (targeted at a specific research window) followed by long gaps, again bypassing the continuous-stimulation pattern that necessitates formal cycling.
When continuous MC4R stimulation has been studied, receptor desensitization has been observed — so the underlying mechanism does apply. It is the usage pattern that makes conventional cycling less central to this class than to the GH secretagogues.
Healing Peptides — Window-Based, Not Cycled
The healing peptides break the cycling template because their mechanisms do not clearly produce the receptor desensitization that cycling is designed to address.
BPC-157 does not have a well-mapped single receptor (see the Mechanism of Action Reference). Its effects appear to work through multiple parallel pathways — angiogenesis, nitric oxide signaling, growth factor modulation. Without a single receptor being continuously agonized, the classical desensitization argument for cycling does not neatly apply.
TB-500 (Thymosin β4) works through actin sequestration — a fundamentally different mechanism from receptor agonism. It is not activating a receptor at all in the conventional sense.
GHK-Cu delivers copper and modulates gene expression rather than driving a receptor pathway to exhaustion.
The practical convention in research protocols is to use these peptides through a defined tissue-repair window — commonly 4 to 6 weeks — sized to the biological process being studied, then discontinued when that window closes rather than cycled indefinitely. If the target tissue requires a longer intervention, the window is extended rather than interrupted with a formal off period.
GLP-1 Agonists — Continuous Use
The GLP-1 class is designed for and used with sustained receptor activation. The multi-day half-lives (semaglutide ~7 days, tirzepatide ~5 days) explicitly produce continuous receptor exposure between weekly doses.
Everything about the modern GLP-1 agonists — lipidation, albumin binding, weekly dosing — is engineered to produce continuous receptor activation. This class is the opposite of pulsatile design.
The GLP-1 receptor tolerates sustained agonism in a way the GHRH and ghrelin receptors do not. There is receptor internalization under agonism, but the class does not appear to lose meaningful effect over the timescales studied. Weekly dosing is the standard, and formal cycling with dedicated off periods is not part of the conventional protocol.
Dose titration — starting low and escalating over weeks — is standard for this class, but that addresses tolerability of side effects, not receptor desensitization. It is a fundamentally different pharmacological consideration from cycling.
Neuroactive & Other Classes
Where the mechanism is less clearly mapped, the cycling convention is correspondingly less firmly grounded. The honest summary for the remaining classes:
Nootropic peptides (Semax, Selank)
Typically used in defined courses — often 2 to 4 weeks — followed by longer breaks, rather than formal on/off cycling. The mechanisms (BDNF induction for Semax; GABA-related for Selank) do not have the same clear desensitization story as the GH axis, but the course-based convention has broadly held in the research literature.
Mitochondrial peptides (MOTS-c, SS-31, Humanin)
These break the cycling template even more decisively than the healing peptides. Their targets are not cell-surface receptors at all. Conventional cycling logic — built around receptor desensitization — does not directly apply. Research protocols vary considerably; there is no dominant "standard cycle" the way there is for GH secretagogues.
Reproductive axis peptides (Gonadorelin, Kisspeptin-10)
This is the class where pulsatile dosing itself is the intervention. Continuous administration of a GnRH agonist actually suppresses LH/FSH release rather than stimulating it — a fundamental property of this axis. Dosing pattern is intrinsic to whether the peptide does anything at all; conventional on/off cycling is a secondary consideration.
Growth factors (IGF-1 LR3, IGF-1 DES, MGF)
Cycling in this class is driven by concerns beyond receptor desensitization — sustained IGF-1R activation raises separate considerations related to cell growth signaling. Research protocols typically use time-limited windows rather than indefinite continuous administration.
How Common Cycle Patterns Actually Arose
Where do specific cycle numbers come from? Understanding the origin explains why they look the way they do and where they should — and shouldn't — be applied.
The "8 weeks on, 4 weeks off" pattern
This pattern originated in the GH secretagogue research literature and reflects two things: roughly how long the pituitary GH-releasing pathways can be continuously stimulated before response measurably drops, and roughly how long a break the axis needs to substantially recover receptor sensitivity. The pattern was not designed as a universal template. It became one through repetition — first extended to peptides in the same class (which was appropriate), then to peptides in different classes (which often was not).
The "5 days on, 2 days off" pattern
A shorter-cycle pattern (weekend break) sometimes cited for GHRPs specifically. The pharmacological argument is that acute desensitization may benefit from even a two-day window, especially for the more potent GHRPs like Hexarelin. Less firmly established than the multi-week convention.
Continuous, no cycle
The pattern used for peptides where cycling accomplishes nothing — GLP-1 agonists, healing peptides used through their repair window, mitochondrial peptides where the mechanism doesn't drive receptor desensitization.
Frequently Asked Questions
Why are peptides cycled?
Peptides are cycled to prevent or reverse receptor desensitization — the process by which cells reduce their response to a signal when that signal is present continuously. For peptides that agonize receptors involved in tightly regulated hormone systems (like the growth hormone axis or the melanocortin system), continuous stimulation reduces effect over time. An off-cycle period allows the receptors to resensitize.
What is receptor desensitization?
Receptor desensitization is the reduced cellular response to a signaling molecule after continuous or repeated exposure. It happens through two main mechanisms: acute desensitization (receptors become temporarily unresponsive on a timescale of minutes to hours) and downregulation (the cell physically reduces the number of receptors on its surface over days to weeks). Both work against sustained peptide effect over time.
Do all peptides need to be cycled?
No. Cycling is only necessary for peptides whose targets are subject to desensitization or downregulation. Growth hormone secretagogues (GHRH analogs and ghrelin mimetics) and melanocortin agonists benefit from cycling because their receptors desensitize. Healing peptides like BPC-157 and TB-500 are generally used continuously through a research window because their mechanisms do not appear to drive the same desensitization. GLP-1 agonists like semaglutide and tirzepatide are typically used continuously because the receptor system tolerates sustained activation.
What is a typical peptide cycle length?
The most commonly cited pattern for GH-releasing peptides is 8 to 12 weeks on followed by 4 weeks off, though the specifics vary by protocol and peptide. For melanocortin agonists like PT-141, cycling is often event-based rather than continuous. Healing peptides are typically used for a defined tissue-repair window (often 4 to 6 weeks) rather than cycled indefinitely. The right cycle length is determined by the desensitization timeline of the specific receptor system, not by convention.
What is tachyphylaxis?
Tachyphylaxis is rapid desensitization to a drug or peptide after repeated doses over a short timescale — often hours to days. It is functionally similar to receptor downregulation but acts faster and is often reversible more quickly. Tachyphylaxis is one of the specific pharmacological reasons certain peptides are dosed intermittently rather than continuously.
How does cycling relate to natural hormone rhythms?
Endogenous hormones like growth hormone are released in pulses, not continuously — the body has evolved rhythmic release patterns specifically to maintain receptor sensitivity. Continuous administration of a GH-releasing peptide flattens that pulsatility, which contributes to desensitization. Cycling and pulsatile dosing (peptides administered several times per day rather than continuously infused) both work to preserve the natural rhythm that healthy signaling depends on.
Does dose titration count as cycling?
No — they address different pharmacological concerns. Dose titration (starting low and gradually escalating) manages tolerability of side effects, particularly for GLP-1 agonists. Cycling (on/off periods) addresses receptor desensitization. A titration schedule is not a substitute for a cycle, and cycling is not a substitute for titration when either is indicated.
Should I cycle CJC-1295 with DAC the same way as CJC-1295 without DAC?
Both target the same GHRH receptor, so both are subject to the same desensitization mechanisms in principle. However, CJC-1295 with DAC has a half-life of 6–8 days, meaning even a single dose maintains receptor exposure for well over a week. This produces sustained rather than pulsatile stimulation and is part of why the DAC variant's usage patterns are more debated within the class. The pharmacological considerations are related but not identical.
Why don't semaglutide and tirzepatide need to be cycled?
The GLP-1 receptor tolerates sustained agonism in a way the GHRH and ghrelin receptors do not. The entire design of the modern GLP-1 agonists — lipidation, albumin binding, multi-day half-lives, weekly dosing — is engineered around continuous receptor activation. The class does not appear to lose meaningful effect over the timescales it is used on, so formal cycling with dedicated off periods is not part of the standard protocol.
All compounds and protocols referenced on this page are discussed strictly for in vitro research and laboratory use. None are approved by the FDA for human consumption, therapeutic use, or veterinary application. This reference is provided for educational and pharmacological reference purposes only and does not constitute medical or dosing advice.
Cycle length ranges are conventions from published research protocols and vary substantially between individual studies and peptide classes. Where cycling patterns are described as "recommended" or "typical," this reflects prevailing convention, not universal rule. For any specific research protocol, follow the study design and manufacturer documentation.